Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
Cautious Outlook on Moderna: Declining Vaccine Demand and …
2 days ago · Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of $38.00. Mani Foroohar’s rating is based on several ...
Moderna reports surprise profit on higher-than-expected COVID …
6 days ago · By Patrick Wingrove. (Reuters) -Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue ...
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
5 days ago · MRNA. Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a loss of $1.89 per share. In the year-ago period, management ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand …
4 days ago · On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion. The company attributed the growth to higher sales in the U.S ...
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
Sep 30, 2024 · The trial aims to enroll approximately 25,000 participants 18 years of age and older globally, including in countries in the Northern Hemisphere (U.S., Canada, UK, Japan), the equatorial region, and the Southern Hemisphere (Australia and countries in South America).
News Details - Moderna
Mar 26, 2024 · In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
News Details - Moderna
Mar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
Sep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Apr 24, 2024 · Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients. Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise.